	US 11,964,060 B2
	Nicotine-containing transparent transdermal therapeutic system
Thomas Hille, Neuwied (DE); Gabriel Wauer, Ahrweiler (DE); Petra Botzem, Andernach (DE); and Frank Seibertz, Bad Breisig (DE)
Assigned to LTS Lohmann Therapie-Systeme AG, Andernach (DE)
Appl. No. 16/488,506
Filed by LTS Lohmann Therapie-Systeme AG, Andernach (DE)
PCT Filed Feb. 26, 2018, PCT No. PCT/DE2018/100168 § 371(c)(1), (2) Date Aug. 23, 2019, PCT Pub. No. WO2018/153413, PCT Pub. Date Aug. 30, 2018.
Claims priority of application No. 10 2017 104 026.9 (DE), filed on Feb. 27, 2017.
Prior Publication US 2020/0230074 A1, Jul. 23, 2020
Int. Cl. A61K 9/70 (2006.01); A61K 31/465 (2006.01); A61K 47/32 (2006.01); A61K 47/34 (2017.01); A61P 25/34 (2006.01); C09J 7/38 (2018.01)

CPC A61K 9/7084 (2013.01) [A61K 31/465 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01); A61P 25/34 (2018.01); C09J 7/385 (2018.01)]

20 Claims

1. A transdermal therapeutic system (TTS), comprising

a) a back layer, impermeable to nicotine,

b) an active-substance-containing layer, comprising nicotine as active substance, wherein the nicotine is in the form of a free base and a vinylpyrrolidone-vinyl acetate copolymer, and wherein the weight ratio of nicotine to vinylpyrrolidone-vinyl acetate copolymer in the active substance-containing layer is 5:1 to 1:1, wherein the residual nicotine content at 24 hours of use on skin is at most 60% at room temperature; and

c) a detachable protective layer,

wherein a joint fraction comprising nicotine and the vinylpyrrolidone-vinyl acetate copolymer in the active-substance-containing layer is 90 to 100% by weight, in relation to the weight of the active-substance-containing layer, wherein the transdermal therapeutic system contains 10 to 400 mg of nicotine.